Table 2 Clinical studies evaluating anti-SARS-CoV-2 mAbs
From: Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
No. | Name | Start date | Latest Status | Developer | Country | References |
|---|---|---|---|---|---|---|
1 | LY-CoV555 (Bamlanivimab) | 5/28/2020 | EUA (11/09/2020) EUA revoked (4/9/2021) | Eli Lilly/AbCellera | Canada/USA | NCT04411628, NCT04427501, NCT04497987, NCT04501978, NCT04518410 [89] |
2 | LY-CoV555 (Bamlanivimab) + LY-CoV016 (Etesevimab) | 6/17/2020 | EUA (2/09/2021) | Eli Lilly/AbCellera/Junshi | Canada/USA | NCT04427501, NCT04497987 [94] |
3 | REGN-COV2 (REGN10933/Casirivimab + REGN10987/Imdevimab) | 6/10/2020 | EUA (11/21/2020) Approved (8/10/2021) | Regeneron | USA | NCT04425629, NCT04426695, NCT04452318 |
4 | S309 (VIR-7831, Sotrovimab) | 8/27/2020 | EUA (5/26/2021) | Vir biotechnology/ GlaxoSmithKline | USA/UK | NCT04501978, NCT04545060 [96] |
5 | AZD7442 (COV2-2130/Cilgavimab + COV2-2196/Tixagevimab) | 8/17/2020 | EUA (12/08/2021) | AstraZeneca/Vanderbilt University Medical Center | UK/USA | NCT04501978, NCT04507256, NCT04625725, NCT04625972 |
6 | TY027 | 6/09/2020 | Phase III | Tychan Pte. LTD | Singapore | NCT04429529, NCT04649515 [303] |
7 | BRII-196 + BRII-198 | 7/12/2020 | Phase III | Brii Bio/TSB Therapeutics/Tsinghua University | China/USA | NCT04518410, NCT04501978 [250] |
8 | CT-P59 (Regdanvimab) | 7/18/2020 | Phase II/III EUA (South Korea) | Celltrion | South Korea | NCT04525079, NCT04593641, NCT04602000 [47] |
9 | BI 767551 (DZIF-10c) | 11/23/2020 | Phase II/III | University of Cologne/he German Center for Infection Research/Boehringer Ingelheim | Germany | NCT04631705, NCT04631666, NCT04822701 [253] |
10 | SCTA01 | 7/24/2020 | Phase II/III | Sinocelltech Ltd/Chinese Academy of Sciences | China | NCT04483375, NCT04644185 [46] |
11 | ADG20 | 4/26/2021 | Phase II/III | Adagio Therapeutics | USA | NCT04805671, NCT04859517 |
12 | MAD0004J08 | 3/1/2021 | Phase II/III | Toscana Life Sciences Sviluppo s.r.l | Italia | NCT04932850, NCT04952805 |
13 | MW33 | 8/7/2020 | Phase II | Mabwell (Shanghai) Bioscience | China | NCT04533048 |
14 | DXP593 | 8/31/2020 | Phase II | Beigene | China | NCT04532294, NCT04551898 [194] |
15 | COVI-AMG (STI-2020) | 2/2/2021 | Phase II | Sorrento Therapeutics | USA | NCT04734860 |
16 | LY-CoV1404 +  LY-CoV555 (Bamlanivimab) + LY-CoV016 (Etesevimab) | 11/18/2020 | Phase II | Eli Lilly/AbCellera/ Junshi | USA | NCT04634409 |
17 | XVR011 | 5/12/2021 | Phase I/II | Exevir Bio BV | Belgium | NCT05017168 |
18 | LY-CoV016 (JS016, Etesevimab) | 6/5/2020 | Phase I | Junshi Biosciences/ Chinese Academy of Sciences/Eli Lilly | China/USA | NCT04441918, NCT04441931, NCT04427501 [51] |
19 | 47D11 | 11/25/2020 | Phase I | Utrecht University/Abbvie/Erasmus MC/Harbor BioMed | Netherlands/China/USA | NCT0464412 [40] |
20 | ADM03820 | 12/4/2020 | Phase II/III | Ology Bioservices | USA | NCT04592549, NCT05142527 |
21 | DXP604 | 12/15/2020 | Phase I | Beigene | China | NCT04669262 |
22 | C144-LS and C-135-LS | 1/11/2021 | Phase II/III | Bristol-Myers Squibb, Rockefeller University | USA | NCT04700163, NCT04518410 [98] |